EN
Zymeworks Can No Longer Hide Behind Its Partners' Milestones
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Zymeworks reports after the close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | -$0.37 (-1.57%) | $0.74 (3.15%) | +$0.41 (+1.77%) | $1.58 (6.83%) |
| 2026-05-07 | -$1.01 (-3.66%) | $1.71 (6.19%) | -$2.71 (-10.19%) | $2.82 (10.60%) |
| 2026-03-02 | +$0.02 (+0.09%) | $1.40 (6.01%) | +$1.14 (+4.89%) | $1.50 (6.45%) |
| 2025-11-06 | -$0.15 (-0.83%) | $0.66 (3.68%) | -$1.44 (-8.04%) | $1.22 (6.80%) |
| 2025-08-07 | -$0.25 (-2.01%) | $0.63 (5.08%) | -$0.14 (-1.15%) | $1.02 (8.39%) |
| 2025-05-08 | -$0.02 (-0.18%) | $0.51 (4.50%) | -$0.02 (-0.13%) | $1.19 (10.47%) |
| 2025-03-05 | +$0.43 (+3.37%) | $0.48 (3.78%) | -$1.05 (-7.97%) | $0.82 (6.22%) |
| 2024-10-31 | -$0.17 (-1.23%) | $0.46 (3.32%) | -$0.42 (-3.07%) | $1.10 (8.03%) |
| Avg Abs Move | 1.62% | 4.46% | 4.65% | 7.97% |
Historical post-earnings moves show significant volatility, with an average absolute Day 0 move of 1.62% and Day +1 move of 4.65%. The most dramatic reaction came in May 2026, when the stock fell 10.19% on Day +1 following the massive earnings miss. The March 2026 report saw a more muted Day 0 reaction (0.09%) but a 4.89% gain on Day +1, suggesting investors looked past the near-term loss to focus on upcoming catalysts. The August 2026 report (most recent) showed a modest 1.57% decline on Day 0 and a 1.77% gain on Day +1, reflecting relatively contained volatility as the market anticipated the upcoming FDA decision.
The Day +1 average of 4.65% suggests investors should prepare for meaningful post-earnings movement, particularly given the transformational nature of this quarter's results. However, the wide range of outcomes—from an 8.04% decline to a 4.89% gain on Day +1—indicates that execution details and forward guidance will be critical in determining direction.
Part 3: What Analysts Are Saying
Zymeworks enjoys overwhelmingly bullish analyst sentiment, with 14 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and 0 Sell ratings among 15 analysts covering the stock. The average recommendation of 4.87 (on a 5-point scale) reflects near-unanimous conviction. This consensus has remained unchanged over the past month, indicating stable confidence heading into the earnings release.
The average price target of $41.21 implies 39% upside from the current level, with a high estimate of $60.00 (102% upside) and a low of $32.00 (8% upside). The wide range reflects differing assumptions about zanidatamab's commercial trajectory, the value of YUPELRI cash flows, and the probability of success for internal pipeline programs. The bullish case centers on the company's transformation into a royalty-driven model with multiple revenue streams, while the more conservative view acknowledges execution risks around integration and clinical development.
Analyst sentiment has improved significantly over recent months, driven by the FDA approval of zanidatamab in GEA, the completion of the Theravance acquisition, and positive Phase 1 data from the internal pipeline. The consensus view is that Zymeworks has successfully de-risked its business model by layering in commercial-stage assets and milestone payments alongside its clinical-stage programs, creating a more balanced risk-reward profile than the typical biotech.
Part 4: Technical Picture
Zymeworks enters earnings with strong technical momentum. The Barchart Technical Opinion currently stands at 100% Buy, up sharply from 88% Buy one week ago and 24% Buy one month ago. This dramatic strengthening reflects the stock's sustained uptrend and improving momentum indicators as shares have climbed above all major moving averages.
- Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings release
- Medium-term (100% Buy): Bullish reading confirms the intermediate-term uptrend remains intact across multiple timeframes
- Long-term (100% Buy): Maximum buy signal reflects the stock's sustained outperformance and structural improvement in the business model
The trend is characterized as Good strength with a Strengthening direction, suggesting the technical setup is supportive for continued gains if the company delivers on expectations.
The stock is trading above its 10-day ($29.19), 20-day ($27.75), 50-day ($27.40), 100-day ($26.09), and 200-day ($25.37) moving averages, though it sits just below the 5-day average ($29.68). This configuration indicates a well-established uptrend with strong support levels below current prices.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $29.68 | 50-Day MA | $27.40 |
| 10-Day MA | $29.19 | 100-Day MA | $26.09 |
| 20-Day MA | $27.75 | 200-Day MA | $25.37 |
The technical picture is constructive heading into earnings, with the stock holding above all key long-term moving averages and momentum indicators flashing maximum bullish readings. The 200-day moving average at $25.37 represents a critical support level more than 16% below current prices, providing a substantial cushion. However, the stock's proximity to the 5-day moving average suggests some near-term consolidation after the recent rally. Given the strong uptrend and bullish technical signals, the setup favors continued strength if Zymeworks delivers on the expected profitability swing and provides confident guidance on integrating YUPELRI and advancing its pipeline. Any disappointment on execution or forward outlook could trigger profit-taking given the year-to-date gains, but the overall technical foundation remains supportive.